Women living with human immunodeficiency virus (WLHIV) are at elevated risk of cervical cancer and precancer. While screening guidelines have changes for women in the general population, optimal screening among WLHIV is less clear.
NA
We will review data using a risk benchmarking approach to compare cervical precancer risks among WLHIV to general population risks that current U.S. guidelines are based on. The analysis identified groups of WLHIV that have low bHSIL+ risks (<1% at 3 years), and others that had much higher risk. How these data compare to and inform screening guidelines is discussed.